The estimated Net Worth of Joseph Frattaroli is at least $363 mil dollars as of 19 May 2022. Mr Frattaroli owns over 3,948 units of Inhibikase Therapeutics stock worth over $63,480 and over the last 3 years he sold IKT stock worth over $0. In addition, he makes $300,000 as Chief Financial Officer at Inhibikase Therapeutics.
Sign up
Mr CPA IKT stock SEC Form 4 insiders trading
Mr has made over 1 trades of the Inhibikase Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 3,948 units of IKT stock worth $2,527 on 19 May 2022.
The largest trade he's ever made was buying 3,948 units of Inhibikase Therapeutics stock on 19 May 2022 worth over $2,527. On average, Mr trades about 987 units every 0 days since 2022. As of 19 May 2022 he still owns at least 48,091 units of Inhibikase Therapeutics stock.
You can see the complete history of Mr Frattaroli stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Joseph Frattaroli CPA biography
Joseph Frattaroli CPA is the Chief Financial Officer at Inhibikase Therapeutics.
What is the salary of Mr CPA?
As the Chief Financial Officer of Inhibikase Therapeutics, the total compensation of Mr CPA at Inhibikase Therapeutics is $300,000. There are 1 executives at Inhibikase Therapeutics getting paid more, with Dr. Milton H. Werner having the highest compensation of $307,341.
How old is Mr CPA?
Mr CPA is 59, he's been the Chief Financial Officer of Inhibikase Therapeutics since . There are no older and 1 younger executives at Inhibikase Therapeutics.
What's Mr CPA's mailing address?
Joseph's mailing address filed with the SEC is 3350 RIVERWOOD PARKWAY SE, SUITE 1900, , ATLANTA, GA, 30339.
Insiders trading at Inhibikase Therapeutics
Over the last 4 years, insiders at Inhibikase Therapeutics have traded over $0 worth of Inhibikase Therapeutics stock and bought 47,537 units worth $63,897 . The most active insiders traders include Milton H. Werner, Elizabeth G. O'farrell y Joseph Frattaroli. On average, Inhibikase Therapeutics executives and independent directors trade stock every 57 days with the average trade being worth of $22,267. The most recent stock trade was executed by Milton H. Werner on 16 August 2022, trading 5,000 units of IKT stock currently worth $4,000.
What does Inhibikase Therapeutics do?
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
What does Inhibikase Therapeutics's logo look like?
Complete history of Mr Frattaroli stock trades at Inhibikase Therapeutics
Inhibikase Therapeutics executives and stock owners
Inhibikase Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Milton H. Werner,
CEO, Pres & Director -
Joseph Frattaroli CPA,
Chief Financial Officer -
Dan Williams,
Controller -
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D.,
Interim Chief Medical Officer & Science Advisor -
Dr. Surendra Singh,
Head of Chemistry, Manufacturing & Controls -
Dr. Roger Rush,
Head of Preclinical Research -
Garth Lees Rolfe,
Chief Financial Officer -
Elizabeth G. O'farrell,
Director -
Paul C Grint,
-
Joseph Frattaroli,
Cheif Financial Officer -
Roy Lester Freeman,
-
Gisele Dion,
-
Dennis N Berman,
-
Milton H. Werner,
President and CEO